Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
To Purchase # 5227SC
|5227SC||10 µg (With Carrier)||$179.00|
|5227SF||10 µg (Carrier Free)||$179.00|
|5227LC||50 µg (With Carrier)||$529.00|
|5227LF||50 µg (Carrier Free)||$529.00|
|$ 0. 00|
Find answers on our FAQs page.
PTM information and tools available.
Mouse Interleukin-17A (mIL-17A) #5227
The purity of recombinant mIL-17A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-17A and staining overnight with Coomassie Blue.Learn more about how we get our images
The production of mouse IL-6 by 3T3 MEFs WT cultured with increasing concentrations of mIL-17A was assessed. Media from cells incubated with mIL-17A for 24 hours was collected and assayed for mouse IL-6 by ELISA and the OD450-OD650 was determined.Learn more about how we get our images
Gallery: Mouse Interleukin-17A (mIL-17A) #5227
- The purity of recombinant mIL-17A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-17A and staining overnight with Coomassie Blue.
- The production of mouse IL-6 by 3T3 MEFs WT cultured with increasing concentrations of mIL-17A was assessed. Media from cells incubated with mIL-17A for 24 hours was collected and assayed for mouse IL-6 by ELISA and the OD450-OD650 was determined.
- Western blot analysis of extracts from 3T3 MEFs WT untreated or treated with mIL-17A for 10 minutes, using Phospho-IκB-α (Ser32) (14D4) Rabbit mAb #2859 (upper) and IκB-α (L35A5) Mouse mAb #4814 (lower).
Recombinant mouse IL-17A (mIL-17A) Thr22-Ala158 (Accession #NP_034682) was expressed in human 293 cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-17A. All lots are greater than 98% pure.Molecular Formula:
Recombinant mIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,377. DTT-reduced protein migrates as a 15-22 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-36 kDa protein. The expected amino-terminal TVKAA of recombinant mIL-17A was verified by amino acid sequencing.Bioactivity:
The bioactivity of recombinant mIL-17A was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 0.4-1.4 ng/ml.Endotoxin:
Less than 0.01 ng endotoxin/1μg mIL-17A.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-17A. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNFα, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4,6). Phosphorylation of some Jaks and Stats has been observed.
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.